Medtronic spends $326 million to buy BPH (benign prostatic hyperplasia) company VidaMed
This article was originally published in Clinica
Medtronic is expanding its urology business with the $326 million acquisition of VidaMed, which has a transurethral needle ablation (TUNA) system for the treatment of benign prostatic hyperplasia (BPH). Under the terms of the deal, each VidaMed shareholder will receive $7.91 per share in cash on consummation of the transaction. This represents a 40% premium on VidaMed's closing price of $5.67 the day before the deal was announced.
You may also be interested in...
Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.
The economic stress on payers caused by the pandemic will cause a setback in the development of payment approaches for regenerative therapy, Blue Cross Blue Shield executive warns.
An interim final rule posted by the CMS this week widens further a series of telehealth exemptions and lab specimen collection payment provisions it has previously issued to help providers during the COVID-19 pandemic.